[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.180.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1964

Experimental Use of Folinic Acid in the Treatment of Toxoplasmosis With Pyrimethamine

Author Affiliations

Detroit; Bethesda, Md
From the Ophthalmology Branch (Dr. Giles), National Institute of Neurological Diseases and Blindness, and from the Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Public Health Service, Department of Health, Education and Welfare.

Arch Ophthalmol. 1964;72(1):82-85. doi:10.1001/archopht.1964.00970020084019
Abstract

Introduction  Summers1 first reported that in treating acute murine toxoplasmosis the combination of folic acid administration with pyrimethamine (Daraprim) therapy did not reverse the antitoxoplasmal action of pyrimethamine and appeared to lessen its toxic action. Cook2 found that in mouse mince-tissue cultures folic acid antagonized the antitoxoplasmal activity of pyrimethamine when the vitamin was present in concentrations eight times that of the drug. In monkey kidney epithelial cell cultures, neither folic acid nor folinic acid had a discernible antagonistic effect on pyrimethamine when the vitamins were added to the culture medium at a concentration 24 times higher than the drug, ie, 12 mg/100 ml:0.5 mg/100 ml. When the drug concentration was reduced to 0.5 mg/ 100 ml, both folic and folinic acid allowed the survival of Toxoplasma gondii in the cells, although no cytopathic effects appeared in the cultures.Frenkel and Hitchings3 and Eyles and Coleman4

First Page Preview View Large
First page PDF preview
First page PDF preview
×